Inhibition of Tumor Growth by RGD Peptide–Directed Delivery of Truncated Tissue Factor to the Tumor Vasculature

Selective activation of blood coagulation in tumor vessels with subsequent tumor infarction is a promising anticancer strategy. To this end, a fusion protein consisting of the extracellular domain of tissue factor [truncated tissue factor (tTF)] was fused to the peptide GRGDSP selectively targeting αv-integrins on tumor endothelial cells. tTF-RGD retained its thrombogenic and integrin-binding activity in vitro. In vivo studies in mice bearing human adenocarcinomas (CCL185), melanoma (M21), and fibrosarcoma (HT1080) revealed that i.v. administration of tTF-RGD induced thrombotic occlusion of tumor vessels resulting in tumor growth retardation or regression in all three types of solid tumors. No apparent side effects, such as thrombosis, in other organs or other treatment-related toxicities were observed. Reduced tumor blood flow in tTF-RGD–treated animals as determined by contrast-enhanced magnetic resonance imaging underlines the proposed mechanism. In conclusion, we consider RGD peptide–directed delivery of tTF as alternative to previously used antibody fusion proteins. Small peptide-directed delivery of coaguligands does not cause immunologic side effects and those caused by accumulation in the reticuloendothelial system. This is the first report to describe the induction of selective thrombosis in tumor vessels by RGD peptide–directed delivery of tTF, which may be a promising strategy for the treatment of cancer.

[1]  P. Comp,et al.  Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. , 1993, Blood.

[2]  R. Santucci,et al.  Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. , 2002, Cancer research.

[3]  B. Coller,et al.  Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel , 1991 .

[4]  Sabita Roy,et al.  Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor‐toxin conjugate , 1997, International journal of cancer.

[5]  P. Comfurius,et al.  Changes in membrane phospholipid distribution during platelet activation. , 1983, Biochimica et biophysica acta.

[6]  W. Berdel,et al.  Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. , 2003, Cancer research.

[7]  M. Ginsberg,et al.  Integrin alpha IIb beta 3 and platelet function. , 1997, Thrombosis and haemostasis.

[8]  W. Berdel,et al.  Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. , 2000, Blood.

[9]  Grietje Molema,et al.  Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature , 1997, Science.

[10]  D. Boger,et al.  Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Taverna,et al.  Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins , 2002, Nature Medicine.

[12]  P. Wright,et al.  Recombinant soluble human tissue factor secreted by Saccharomyces cerevisiae and refolded from Escherichia coli inclusion bodies: glycosylation of mutants, activity and physical characterization. , 1995, The Biochemical journal.

[13]  M. Bednarski,et al.  Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.

[14]  J. Freyssinet,et al.  Physiopathological Significance of Catalytic Phospholipids in the Generation of Thrombin , 1996, Seminars in thrombosis and hemostasis.

[15]  Vasilis Ntziachristos,et al.  Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. , 2003, Radiology.

[16]  A. Gazdar,et al.  Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  K. Schulmann,et al.  [Regression grading of neoadjuvant non-small-cell lung carcinoma treatment]. , 1997, Der Pathologe.

[18]  K. Müller,et al.  Regressionsgrading neoadjuvant behandelter nichtkleinzelliger Lungenkarzinome , 1997, Der Pathologe.

[19]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[20]  J. Rosing,et al.  Development of procoagulant binding sites on the platelet surface. , 1985, Advances in experimental medicine and biology.

[21]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[22]  J. Healey,et al.  Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Timo Sorsa,et al.  Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.

[24]  Fulvio Magni,et al.  Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) , 2000, Nature Biotechnology.

[25]  M. Bally,et al.  Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. , 2003, Biochimica et biophysica acta.

[26]  A. Pfeifer,et al.  Matrix metalloproteinase/integrin interactions as target for anti-angiogenic treatment strategies. , 2002, Annals of hematology.

[27]  L. Zardi,et al.  A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors , 1989, The Journal of cell biology.

[28]  S. Ran,et al.  Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. , 1998, Cancer research.

[29]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[30]  L. Khawli,et al.  Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. , 2003, Cancer research.

[31]  P. Comp,et al.  Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation , 1993 .

[32]  D. Boger,et al.  Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin alpha(V)beta(3). , 2001, Journal of the American Chemical Society.

[33]  R Pasqualini,et al.  NG2 proteoglycan-binding peptides target tumor neovasculature. , 1999, Cancer research.

[34]  A. Rehemtulla,et al.  Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. , 1991, The Journal of biological chemistry.

[35]  H. Kosmehl,et al.  Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. , 2001, Cancer research.

[36]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[37]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[38]  David,et al.  Selection of Peptides Binding to the a 5 pl Integrin from Phage Display Library , 2001 .

[39]  David W. Banner,et al.  The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor , 1996, Nature.

[40]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[41]  R. Hynes,et al.  Extensive Vasculogenesis, Angiogenesis, and Organogenesis Precede Lethality in Mice Lacking All αv Integrins , 1998, Cell.

[42]  E. Ruoslahti.  Targeting tumor vasculature with homing peptides from phage display. , 2000, Seminars in cancer biology.

[43]  Harold E. Dvorak,et al.  Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels , 1991, The Journal of experimental medicine.

[44]  I. Verma,et al.  Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Detmar,et al.  Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  E. Thiel,et al.  Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. , 1993, Blood.

[47]  E. Ruoslahti,et al.  Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. , 1993, The Journal of biological chemistry.

[48]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[49]  S. Shattil,et al.  Integrin signaling: the platelet paradigm. , 1998, Blood.